SCHEMBL1462583

SCHEMBL1462583

Nc1cccc(-c2ccnc(CC3CCOCC3)c2)n1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAP4K4 O95819 4/20 0.39
▸ ASIC3 Q9UHC3 1/20 0.38
▸ IRAK4 Q9NWZ3 2/20 0.38
▸ MCHR1 Q99705 1/20 0.37
▸ PIK3CA P42336 2/20 0.36
▸ PIK3CD O00329 1/20 0.36
▸ HTR6 P50406 5/20 0.36
▸ JAK2 O60674 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ PDPK1 O15530 1/20 0.35
▸ DHFR P00374 1/20 0.35
▸ DCPS Q96C86 1/20 0.35
▸ CYP2C19 P33261 2/20 0.35
▸ KCNH2 Q12809 2/20 0.35
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ HIF1A Q16665 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2144739 0.77 MCHR1 (0.43) MCHR1DHFRDCPS
SCHEMBL1224601 0.76 MCHR1 (0.37) MAP4K4ASIC3MCHR1PIK3CAPIK3CD
SCHEMBL1225532 0.73 CCNT1 (0.52) MAP4K4IRAK4KCNH2HIF1A
SCHEMBL31403748 0.71 DHFR (0.40) MCHR1PIK3CAPIK3CDHTR6DHFR
SCHEMBL901899 0.70 ASIC3 (0.57) ASIC3IRAK4PDPK1KCNH2
SCHEMBL30629342 0.70 MCHR1 (0.39) MAP4K4IRAK4MCHR1PIK3CAPIK3CD
SCHEMBL1224598 0.69 CCNT1 (0.37) IRAK4MCHR1PIK3CAPIK3CDMAPK1
SCHEMBL2143997 0.69 MCHR1 (0.50) MCHR1DHFRDCPS
SCHEMBL20385485 0.68 SMN1; SMN2 (0.43) MAPK1HIF1A
SCHEMBL901581 0.67 MAP4K4 (0.52) MAP4K4ASIC3MAPK1PDPK1DHFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2473499-A1 BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Novartis AG (CH) 2012-07-11 — — EP disclosed
WO-2011026911-A1 BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES NOVARTIS AG (CH) 2011-03-10 — — WO disclosed
Send feedback